Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 97, Issue 1, Pages 29-36Publisher
WILEY-BLACKWELL
DOI: 10.1002/cpt.1
Keywords
-
Categories
Funding
- Greenwall Faculty Scholarship in Bioethics
- Robert Wood Johnson Foundation
- Harvard Program in Therapeutic Science
Ask authors/readers for more resources
New prescription drugs receive approval from the US Food and Drug Administration (FDA) based on tests establishing safety and adequate and well-controlled trials demonstrating substantial evidence of efficacy. However, a number of legislative and regulatory initiatives, the most recent being the breakthrough therapy designation created in 2012, give the FDA flexibility to approve drugs on the basis of less rigorous data in situations of greater clinical need. These expedited development and review pathways now contribute to a majority of all new drug approvals and have important benefits in encouraging efficient availability of transformative drugs. They also have a number of risks, including a heightened possibility that the drugs will be discovered to be ineffective or unsafe after widespread use, and confusion by patients and physicians over what it means for a product to be FDA approved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available